Yes, an FSA generally covers tirzepatide when a physician prescribes it to treat a diagnosed condition such as obesity, type 2 diabetes, hypertension, or heart disease. It does not cover tirzepatide used for cosmetic weight loss or general wellness. Approval usually takes more paperwork than a routine prescription, and the rules around compounded versions have tightened.
Why Tirzepatide Qualifies Under IRS Rules
Two rules in IRS Publication 502 do the work. Prescribed medicines are includible medical expenses: “You can include in medical expenses amounts you pay for prescribed medicines and drugs.” And weight-loss treatment counts when it addresses a diagnosed disease: “You can include in medical expenses amounts you pay to lose weight if it is a treatment for a specific disease diagnosed by a physician (such as obesity, hypertension, or heart disease).”1IRS. Publication 502, Medical and Dental Expenses
The IRS treats obesity itself as a qualifying disease. Its updated FAQ on nutrition and wellness expenses confirms weight-loss programs and related treatments are eligible when they treat “a specific disease diagnosed by a physician (such as obesity, diabetes, hypertension, or heart disease).”2IRS. Frequently Asked Questions About Medical Expenses Related to Nutrition, Wellness, and General Health
Tirzepatide is a prescription drug for FDA-recognized conditions, so it fits when the prescription is tied to a diagnosis. The IRS makes no distinction between Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management in adults with obesity, or overweight with comorbidities). Both need the same things for reimbursement: a prescription, a diagnosis, and supporting paperwork.3Raleigh News and Observer. Weight Loss Medications and HSA/FSA Eligibility
What Your FSA Administrator Will Ask For
A prescription alone often isn’t enough. Weight-loss medications draw extra scrutiny because they sit near the line between treating disease and general weight management, so most administrators want a package of documents before approving reimbursement.
- A valid prescription from a licensed provider, ideally noting a diagnosis code tied to a recognized condition such as obesity (ICD-10 code E66), type 2 diabetes, or a related comorbidity.
- A Letter of Medical Necessity describing your condition, why tirzepatide is the appropriate treatment, your treatment history, and the expected duration of treatment. Federal employees using FSAFEDS also need an attestation that the treatment is not for general health or cosmetic purposes.4Miami Herald. Weight Loss Medications and HSA/FSA Eligibility5FSAFEDS. Letter of Medical Necessity Form
- Itemized receipts showing the medication name, dosage, quantity, date, and cost. Ask the pharmacy to print “tirzepatide” or the brand name on the receipt; generic codes and abbreviations can slow processing.
One practical note about the debit card. A decline at the pharmacy counter does not always mean the expense is ineligible. Merchant category codes sometimes block otherwise qualified transactions at the point of sale. Pay out of pocket, then submit a manual reimbursement claim through your plan’s portal with the documentation attached.6GoodRx. Weight Loss Items: HSA Eligible Expense
Why Claims Get Denied and How to Fix Them
Vague documentation is the leading cause. A prescription that lists only “weight management” without linking the drug to a diagnosed condition often gets rejected. Administrators want a specific medical diagnosis, not a general purpose.6GoodRx. Weight Loss Items: HSA Eligible Expense Other frequent triggers are a missing or expired Letter of Medical Necessity, a diagnosis the administrator considers insufficient, and receipts that aren’t itemized.
If you receive a denial, start with the notice itself. It should state the specific reason and any documentation still needed. Ask your physician for an updated Letter of Medical Necessity that speaks directly to that reason, including the ICD-10 code and a clear statement linking tirzepatide to your condition. Submit the corrected paperwork within the deadline stated on the notice. FSA plans typically allow up to three levels of appeal if the first attempt fails.7Truemed. Why Was My Claim Denied
The cleanest strategy is to get the paperwork right before you buy. Call your administrator, confirm what they require, and have the Letter of Medical Necessity in hand before you fill the prescription.
How Much of the Cost Your FSA Can Absorb
For the 2026 plan year, the IRS set the health FSA contribution limit at $3,400, a $100 increase from 2025. Plans that permit a carryover can move up to $680 of unused funds into the next year.8HealthEquity. IRS Raises FSA, Commuter Contribution Limits for 2026
Tirzepatide’s out-of-pocket cost swings widely. Brand-name pens at retail run about $1,059 to $1,086 per month. Eli Lilly’s LillyDirect self-pay vial program lists $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $499 for higher doses. A year at the lowest self-pay price comes to roughly $3,588, slightly above the FSA limit but largely offsettable. At full retail, the annual cost can top $13,000, and FSA funds would cover only a fraction.9InjectCo. Tirzepatide Price 2026
One restriction to know about. Eli Lilly’s Zepbound savings card prohibits seeking FSA or HSA reimbursement for any amount covered by the card. Patients who use it agree not to seek payment from “any health savings, flexible spending, or other healthcare reimbursement accounts” for the savings received.10Eli Lilly. Zepbound Savings Combining both would violate those terms and could cost you savings-card eligibility.
Compounded Tirzepatide Is a Different Situation
Compounded tirzepatide was widely sold during the national drug shortage, which ran through 2024. The FDA determined the shortage was resolved in December 2024. Its enforcement discretion periods for compounders ended in February 2025 for state-licensed pharmacies and March 2025 for outsourcing facilities.11FDA. FDA Memorandum on Tirzepatide Shortage Resolution As of 2026, tirzepatide does not appear on the FDA drug shortage list or the 503B bulk drug substances list.12FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
Under current law, a 503A pharmacy can compound a drug that is “essentially a copy” of a commercially available product only if the prescriber documents a clinically significant difference for an individual patient, or if the pharmacy fills four or fewer such prescriptions per month. Outside those narrow exceptions, compounding tirzepatide is effectively prohibited.12FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize Some online providers still market compounded tirzepatide, but those products are not FDA-approved and the legal footing has narrowed. If a compounded version obtained through legitimate channels is prescribed for a diagnosed condition, FSA eligibility follows the same rules as the brand-name drug: prescription, itemized receipt naming the medication, and a Letter of Medical Necessity when the administrator asks for one.
FSA and HSA: Same Rule, Different Risks
The IRS eligibility test is identical for both accounts: tirzepatide has to be prescribed for a diagnosed condition. The practical differences show up in how each account handles paperwork and mistakes.
FSA administrators often want the Letter of Medical Necessity upfront, before releasing funds. HSA holders generally spend at their own discretion but need to keep records in case the IRS asks later.3Raleigh News and Observer. Weight Loss Medications and HSA/FSA Eligibility
The penalty structures diverge too. If an FSA expense is later deemed ineligible, the employer may require repayment, but there is no IRS tax penalty. Ineligible HSA withdrawals are treated as taxable income, and account holders under 65 face an additional 20 percent penalty on top of the tax. That extra penalty goes away at 65, though the withdrawal is still taxable.3Raleigh News and Observer. Weight Loss Medications and HSA/FSA Eligibility